GLP-1 (Glucagon-like peptide-1) apps are designed to support individuals who are prescribed GLP-1 receptor agonists, a class of medications commonly used to treat type 2 diabetes
They can be administered as injections once a day, and some even once a week
This leads to conditions such as: When women suffer from a Semaglutide therapy Lose weight, this cycle can partially normalize again
By lowering insulin levels, they can help reduce excess androgen production, which in turn may regulate menstrual cycles, decrease acne, and lessen unwanted hair growth
Retatrutide is a next-generation synthetic peptide acting as a triple receptor agonist, simultaneously targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors